Investors

Home / Investors / Press Releases

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October

Download PDF

NEWARK, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming investor conferences, including the 2018 Cantor Global Healthcare Conference, the LEERINK Partners Roundtable Series: Rare Disease & Oncology, and the ROTH Battle of the NASH Thrones Investor Conference.

2018 Cantor Global Healthcare Conference 
Date: Monday, October 1
Time: 8:55am Eastern Time
Location: Intercontinental Barclay New York Hotel
Webcast: http://ir.cymabay.com/events
   
LEERINK Partners Roundtable Series:  Rare Disease & Oncology
Date: Tuesday, October 2
Time: 8:30am Eastern Time
Location: Lotte New York Palace Hotel
Webcast: http://ir.cymabay.com/events
   
ROTH Battle of the NASH Thrones Investor Conference
Date: Wednesday, October 17
Time: Panel discussions and 1-on-1 meetings
Location: Park Hyatt New York Hotel

About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH).

For additional information about CymaBay visit www.cymabay.com.

Contact:              
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com

CBAY Logo.jpg

Source: CymaBay Therapeutics, Inc.